Peter Flynn
Co-Founder & Strategic AdvisorDr. Peter Flynn, Ph.D., is also known as Pete, is President, CEO & Director of Arialys Therapeutics, Inc. from June 2024. He Co-founded Artiva Biotherapeutics, Inc. and has been its Strategic Advisor since May 2023. He served as Chief Operating Officer of Artiva Biotherapeutics, Inc. since June 2020 until May 2023. He was Chief Technology Officer at Artiva Biotherapeutics, Inc. from April 2019 to June 2020. He oversaw business development and strategy, research, manufacturing and corporate operations. During his time at Artiva, the company achieved significant financing, clearance of several IND applications, the establishment of a built-to-fit office, research labs and internal GMP manufacturing capability and corporate partnerships with Merck and Affimed. Dr. Flynn served as Executive Vice President, Global Head of Development, of Orexigen Therapeutics, Inc., a pharmaceutical company, from February 2015 to July 2018 where he oversaw the post-marketing development and regulatory aspects of Contrave, an FDA-approved weight-loss prescription medication. Coordinating staff across the U.S., E.U. and MENA regions, he collaborated with the commercial team to ensure effective medical and regulatory support for global partnerships and direct-to-consumer and telemedicine campaigns for Contrave. Dr. Flynn also served as Senior Vice President, Early Program Development, of Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, from May 2009 to February 2015, where he was responsible for the development of the iPSC platform and was a member of the senior executive team for Fate’s IPO in 2013. Dr. Flynn has executive leadership experience in the biotech industry, from private start-ups to established publicly traded companies, scaling companies through key financings and pharma partnerships, advancing novel therapeutics from scientific breakthrough to the clinic and commercializing FDA-approved medicines. He was Vice President of Research at Ren Pharmaceuticals, Inc. from March 2007 and May 2009. In his career, Dr. Flynn served as head of biochemistry at the antibody therapeutics company, KaloBios Pharmaceuticals Inc. Dr. Flynn started his industry career at the antibody therapeutics company KaloBios, where as head of biochemistry he helped build both the platform technology and therapeutic pipeline. Dr. Flynn received his B.Sc. in Molecular Biology from University College London and his Ph.D. in Biochemistry from the Imperial Cancer Research Fund in association with University College London and was a postdoctoral fellow at the University of California, San Francisco, Cancer Center.
Positions
- Company NameArtiva Biotherapeutics, Inc.Stock CodeARTVPositionCo-Founder & Strategic AdvisorColleagues
- FAFred AslanCEO, Principal Financial & Accounting Officer and Director
- BFBrian F. DanielsIndependent Chairman of the Board
- GDGines Diego MirallesPresident and Head of Research & Development
- JKJennifer Kinsbruner BushChief Operating Officer
- CPChristopher P. HoranChief Technical Operations Officer
- LSLaura StoppelIndependent Director
- RTRichard T. MaziarzAdvisor
